Risk-stratified sequential treatment of de-novo post-transplant lymphoproliferative disorder (PTLD) with Ibrutinib and Rituximab (IR) and IR-CHOP

Project Details

Short titleRisk-stratified sequential treatment of de-novo post-transplant lymphoproliferative disorder (PTLD) with Ibrutinib and Rituximab (IR) and IR-CHOP
StatusActive
Effective start/end date1/12/1531/12/23

Funding

  • BLOODWISE
  • Janssen-Cilag Limited